![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/03/Afbeelding1-1024x768.jpg)
ASH 2021 Focus on CAR T-Cell Therapy
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/03/panel-compilatietekst-2-277x300.png)
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/03/Afbeelding1-1024x768.jpg)
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/12/podcast-icoon-1.jpg)
ASH 2021 Focus on CAR T-Cell Therapy Podcast
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/ash3-e1646836531755-1024x775.png)
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
CONTENTS
Online First
CAR T-cell Therapy
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/03/Dr-Kelly.png)
Most re-hospitalisations within first month from CAR T-cell infusion
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/ash10-e1646735574623.png)
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/Dr-Sattva-S-Nellapu.png)
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/ash4.png)
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/ash3-e1646836531755-1024x775.png)
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
![](https://conferences.medicom-publishers.com/wp-content/uploads/2022/02/ash2-e1646900911377.png)